Stručni rad
https://doi.org/10.3325/cmj.2022.63.176
The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and metaanalysis
Anna Mrzljak
orcid.org/0000-0001-6270-2305
; Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia
Maja Cigrovski Berković
orcid.org/0000-0003-0750-9785
; Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, University Hospital Dubrava, Zagreb, Croatia
Francesco Giovanardi
; General Surgery and Organ Transplantation Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy
Lai Quirino
; Sapienza University of Rome, Rome, Italy
Sažetak
Aim To evaluate the effect of diabetes mellitus type 2
(T2DM) on the outcomes after treatment of hepatocellular
carcinoma (HCC).
Methods PubMed and Cochrane Central Register of
Controlled Trials Databases were systematically searched.
Three HCC clinical outcomes were explored: death, progressive disease after locoregional therapies, and recurrence. Sub-analysis was performed according to the use of
potentially curative (resection, transplantation, termo-ablation) or non-curative therapies. Odds ratios (OR) and 95%
confidence intervals (CI) were calculated to compare the
pooled data between T2DM and non-T2DM groups.
Results A total of 27 studies were analyzed. Overall, 85.2%
of articles were from Asia. T2MD was associated with an increased risk of death (OR 3.60; 95%CI 2.18-5.95; P<0.001),
irrespective of the treatment approach: curative (OR 1.30
95%CI 1.09-1.54; P=0.003) or non-curative (OR 1.05; 95%CI
1.00-1.10; P=0.045), increased HCC recurrence (OR 1.30;
95%CI 1.03-1.63; P=0.03), and increased disease progressiveness (OR 1.24; 95%CI 1.09-1.41; P=0.001).
Conclusions Current data provide strong evidence that
T2DM unfavorably affects HCC progression and recurrence, and patients’ survival after treatment, irrespective of
the approach used.
Ključne riječi
Hrčak ID:
279013
URI
Datum izdavanja:
21.4.2022.
Posjeta: 304 *